loxoprofen has been researched along with Edema in 4 studies
loxoprofen: RN given refers to parent cpd without isomeric designation; structure in first source
loxoprofen : A monocarboxylic acid that is propionic acid in which one of the hydrogens at position 2 is substituted by a 4-[(2-oxocyclopentyl)methyl]phenyl group. A prodrug that is rapidly converted into its active trans-alcohol metabolite following oral administration.
Edema: Abnormal fluid accumulation in TISSUES or body cavities. Most cases of edema are present under the SKIN in SUBCUTANEOUS TISSUE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Lornoxicam exhibits strong analgesic but weak antipyretic effects in rats with paw inflammation." | 7.75 | The importance of brain PGE2 inhibition versus paw PGE2 inhibition as a mechanism for the separation of analgesic and antipyretic effects of lornoxicam in rats with paw inflammation. ( Arai, I; Futaki, N; Harada, M; Hashimoto, Y; Honma, Y; Hoshi, K; Nakaike, S; Sugimoto, M, 2009) |
| "We previously reported that 2-fluoroloxoprofen has lower gastric ulcerogenic activity than loxoprofen, a nonsteroidal anti-inflammatory drug (NSAID) without selectivity for COX-2." | 3.78 | Synthesis and biological evaluation of derivatives of 2-{2-fluoro-4-[(2-oxocyclopentyl)methyl]phenyl}propanoic acid: nonsteroidal anti-inflammatory drugs with low gastric ulcerogenic activity. ( Asano, T; Ishihara, T; Miyata, K; Mizushima, T; Okamoto, Y; Otsuka, M; Suemasu, S; Tanaka, K; Yamakawa, N, 2012) |
| "Lornoxicam exhibits strong analgesic but weak antipyretic effects in rats with paw inflammation." | 3.75 | The importance of brain PGE2 inhibition versus paw PGE2 inhibition as a mechanism for the separation of analgesic and antipyretic effects of lornoxicam in rats with paw inflammation. ( Arai, I; Futaki, N; Harada, M; Hashimoto, Y; Honma, Y; Hoshi, K; Nakaike, S; Sugimoto, M, 2009) |
| " The anti-inflammatory potency of NS-398 in rat carrageenin-induced edema was as potent as that of indomethacin and 8 times more potent than diclofenac." | 3.68 | NS-398, a novel non-steroidal anti-inflammatory drug with potent analgesic and antipyretic effects, which causes minimal stomach lesions. ( Arai, I; Futaki, N; Hamasaka, Y; Higuchi, S; Iizuka, H; Otomo, S; Yoshikawa, K, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yamakawa, N | 1 |
| Suemasu, S | 1 |
| Okamoto, Y | 1 |
| Tanaka, K | 1 |
| Ishihara, T | 1 |
| Asano, T | 1 |
| Miyata, K | 1 |
| Otsuka, M | 1 |
| Mizushima, T | 1 |
| Futaki, N | 2 |
| Harada, M | 1 |
| Sugimoto, M | 1 |
| Hashimoto, Y | 1 |
| Honma, Y | 1 |
| Arai, I | 2 |
| Nakaike, S | 1 |
| Hoshi, K | 1 |
| Noguchi, M | 1 |
| Kimoto, A | 1 |
| Gierse, JK | 1 |
| Walker, MC | 1 |
| Zweifel, BS | 1 |
| Nozaki, K | 1 |
| Sasamata, M | 1 |
| Yoshikawa, K | 1 |
| Hamasaka, Y | 1 |
| Higuchi, S | 1 |
| Iizuka, H | 1 |
| Otomo, S | 1 |
4 other studies available for loxoprofen and Edema
| Article | Year |
|---|---|
Synthesis and biological evaluation of derivatives of 2-{2-fluoro-4-[(2-oxocyclopentyl)methyl]phenyl}propanoic acid: nonsteroidal anti-inflammatory drugs with low gastric ulcerogenic activity.
Topics: Aniline Compounds; Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Cyclooxygenase 1; | 2012 |
The importance of brain PGE2 inhibition versus paw PGE2 inhibition as a mechanism for the separation of analgesic and antipyretic effects of lornoxicam in rats with paw inflammation.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Cel | 2009 |
Enzymologic and pharmacologic profile of loxoprofen sodium and its metabolites.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase | 2005 |
NS-398, a novel non-steroidal anti-inflammatory drug with potent analgesic and antipyretic effects, which causes minimal stomach lesions.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Carrageenan; Cyclooxygena | 1993 |